Crossmark Global Holdings’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.48M | Buy |
+23,619
| New | +$4.44M | 0.06% | 283 |
|
|
2026
Q1 | – | Sell |
-26,915
| Closed | -$4.95M | – | 1240 |
|
|
2025
Q4 | $4.95M | Sell |
26,915
-416
| -2% | -$73K | 0.07% | 257 |
|
|
2025
Q3 | $4.19M | Buy |
27,331
+226
| +0.8% | +$34.2K | 0.06% | 277 |
|
|
2025
Q2 | $3.79M | Sell |
27,105
-209
| -0.8% | -$29.3K | 0.06% | 291 |
|
|
2025
Q1 | $4.02M | Buy |
27,314
+753
| +3% | +$109K | 0.07% | 273 |
|
|
2024
Q4 | $3.48M | Sell |
26,561
-158
| -0.6% | -$22.1K | 0.06% | 291 |
|
|
2024
Q3 | $4.16M | Buy |
26,719
+6,478
| +32% | +$1.05M | 0.07% | 267 |
|
|
2024
Q2 | $3.16M | Buy |
20,241
+651
| +3% | +$98K | 0.06% | 302 |
|
|
2024
Q1 | $2.65M | Sell |
19,590
-657
| -3% | -$87K | 0.05% | 348 |
|
|
2023
Q4 | $2.73M | Buy |
20,247
+474
| +2% | +$61.6K | 0.06% | 331 |
|
|
2023
Q3 | $2.69M | Buy |
19,773
+24
| +0.1% | +$3.28K | 0.06% | 315 |
|
|
2023
Q2 | $2.82M | Buy |
19,749
+855
| +5% | +$126K | 0.06% | 327 |
|
|
2023
Q1 | $2.62M | Buy |
18,894
+119
| +0.6% | +$16K | 0.06% | 334 |
|
|
2022
Q4 | $2.55M | Sell |
18,775
-276
| -1% | -$34.6K | 0.06% | 331 |
|
|
2022
Q3 | $2.09M | Buy |
19,051
+2,626
| +16% | +$333K | 0.06% | 341 |
|
|
2022
Q2 | $2.17M | Sell |
16,425
-895
| -5% | -$117K | 0.06% | 356 |
|
|
2022
Q1 | $2.3M | Buy |
17,320
+1,470
| +9% | +$176K | 0.05% | 373 |
|
|
2021
Q4 | $1.85M | Hold |
15,850
| – | – | 0.04% | 438 |
|
|
2021
Q3 | $1.9M | Buy |
15,850
+2,775
| +21% | +$323K | 0.04% | 398 |
|
|
2021
Q2 | $1.57M | Sell |
13,075
-830
| -6% | -$91.1K | 0.04% | 468 |
|
|
2021
Q1 | $1.38M | Sell |
13,905
-5,808
| -29% | -$584K | 0.03% | 490 |
|
|
2020
Q4 | $1.97M | Sell |
19,713
-3,859
| -16% | -$409K | 0.05% | 377 |
|
|
2020
Q3 | $2.58M | Buy |
23,572
+660
| +3% | +$73.4K | 0.07% | 281 |
|
|
2020
Q2 | $2.42M | Sell |
22,912
-942
| -4% | -$97.3K | 0.07% | 293 |
|
|
2020
Q1 | $2.13M | Buy |
23,854
+1,130
| +5% | +$106K | 0.08% | 274 |
|
|
2019
Q4 | $2.27M | Buy |
22,724
+1,095
| +5% | +$103K | 0.06% | 331 |
|
|
2019
Q3 | $1.93M | Sell |
21,629
-10,395
| -32% | -$901K | 0.06% | 365 |
|
|
2019
Q2 | $2.64M | Buy |
32,024
+1,355
| +4% | +$106K | 0.07% | 303 |
|
|
2019
Q1 | $2.48M | Buy |
30,669
+500
| +2% | +$39.4K | 0.07% | 312 |
|
|
2018
Q4 | $2.29M | Sell |
30,169
-385
| -1% | -$30.1K | 0.07% | 309 |
|
|
2018
Q3 | $2.42M | Buy |
30,554
+12,184
| +66% | +$922K | 0.06% | 350 |
|
|
2018
Q2 | $1.29M | Sell |
18,370
-29,930
| -62% | -$2.15M | 0.03% | 513 |
|
|
2018
Q1 | $3.38M | Sell |
48,300
-12,701
| -21% | -$880K | 0.09% | 281 |
|
|
2017
Q4 | $4.23M | Sell |
61,001
-270
| -0.4% | -$18.2K | 0.1% | 241 |
|
|
2017
Q3 | $4.15M | Buy |
+61,271
| New | +$3.87M | 0.11% | 230 |
|
|
2016
Q3 | $4.15M | Buy |
+61,271
| New | +$4.01M | 0.11% | 230 |
|
Other funds holding AZN
EP
IA
Crossmark Global Holdings's AZN Position: Q2 2026 in Review
Crossmark Global Holdings opened a new position in AstraZeneca (AZN) in Q2 2026: 23,619 shares worth $4.48M. The stake represents 0.06% of the portfolio and ranks #283 among its holdings. This is a return to the name: Crossmark Global Holdings previously reported a position in AZN as recently as Q4 2025.
Crossmark Global Holdings first reported a position in AZN in Q3 2016 and has held it in 36 quarters since. The position peaked at $4.95M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Crossmark Global Holdings held 23,619 shares of AstraZeneca worth $4.48M as of Q2 2026.
- AstraZeneca was a new Crossmark Global Holdings position in Q2 2026.
- AstraZeneca made up 0.06% of Crossmark Global Holdings's portfolio in Q2 2026, its #283 holding.
- Crossmark Global Holdings first reported a position in AstraZeneca in Q3 2016 and has held it in 36 quarters since.
- Crossmark Global Holdings's AstraZeneca position peaked at $4.95M in Q4 2025.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.